AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 281: E1191-E1196, 2001;
0193-1849/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (45)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolthers, T.
Right arrow Articles by Ho, K. K. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolthers, T.
Right arrow Articles by Ho, K. K. Y.
Vol. 281, Issue 6, E1191-E1196, December 2001

Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women

Troels Wolthers1, David M. Hoffman1, Ailish G. Nugent1, Mark W Duncan2, Margot Umpleby2, and Ken K. Y. Ho1

1 The Garvan Institute of Medical Research, St. Vincent's Hospital and Biomedical Mass Spectrometry Unit, University of New South Wales, Sydney, New South Wales 2010, Australia; and 2 Endocrine and Diabetic Unit, St. Thomas's Hospital, London SE1 7EH, United Kingdom

We have determined whether oral estrogen reduces the biological effects of growth hormone (GH) in GH-deficient (GHD) women compared with transdermal estrogen treatment. In two separate studies, eight GHD women randomly received either oral or transdermal estrogen for 8 wk before crossing over to the alternate route of administration. The first study assessed the effects of incremental doses of GH (0.5, 1.0, 2.0 IU/day for 1 wk each) on insulin-like growth factor I (IGF-I) levels during each estrogen treatment phase. The second study assessed the effects of GH (2 IU/day) on lipid oxidation and on protein metabolism using the whole body leucine turnover technique. Mean IGF-I level was significantly lower during oral estrogen treatment (P < 0.05) and rose dose dependently during GH administration by a lesser magnitude (P < 0.05) compared with transdermal treatment. Postprandial lipid oxidation was significantly lower with oral estrogen treatment, both before (P < 0.05) and during (P < 0.05) GH administration, compared with transdermal treatment. Protein synthesis was lower during oral estrogen both before and during GH administration (P < 0.05). Oral estrogen antagonizes several of the metabolic actions of GH. It may aggravate body composition abnormalities already present in GHD women and attenuate the beneficial effects of GH therapy. Estrogen replacement in GHD women should be administered by a nonoral route.

insulin-like growth factor I; lipid oxidation; protein turnover


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. A van der Klaauw, N. R Biermasz, P. M J Zelissen, A. M Pereira, E. G W M Lentjes, J. W A Smit, S. W van Thiel, J. A Romijn, and F. Roelfsema
Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism
Eur. J. Endocrinol., December 1, 2007; 157(6): 709 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
W.-J. A. Tsai, K. M. McCormick, D. A. Brazeau, and G. A. Brazeau
Estrogen Effects on Skeletal Muscle Insulin-Like Growth Factor 1 and Myostatin in Ovariectomized Rats
Experimental Biology and Medicine, November 1, 2007; 232(10): 1314 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Sjogren, K.-C. Leung, W. Kaplan, M. Gardiner-Garden, J. Gibney, and K. K. Y. Ho
Growth hormone regulation of metabolic gene expression in muscle: a microarray study in hypopituitary men
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E364 - E371.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. G. Burt, J. Gibney, and K. K. Y. Ho
Protein metabolism in glucocorticoid excess: study in Cushing's syndrome and the effect of treatment
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1426 - E1432.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Gibney, T. Wolthers, G. Johannsson, A. M. Umpleby, and K. K. Y. Ho
Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E266 - E271.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber
Consensus statement on the management of the GH-treated adolescent in the transition to adult care
Eur. J. Endocrinol., February 1, 2005; 152(2): 165 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema
Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online